

Dragon, Karen E. (CDC/NIOSH/EID)

From: clyde.cole@ge.com
Sent: Thursday, August 04, 2011 3:14 PM
To: NIOSH Docket Office (CDC)
Subject: 190 - NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012: Proposed Additions and Deletions to the NIOSH Hazardous Drug List Comments

Name

Clyde N. Cole, RPh, FAPhA

Organization

GE Healthcare

Email

clyde.cole@ge.com

Address

7071 N. Greenview Ave
Chicago, IL 60626
USA

Comments

As a practicing nuclear pharmacist, I support the removal of ibritumomab tiuxetan and tositumomab from the HIOSH Hazardous Drugs List.

I also suggests the removal of pentetate calcium trisodium from the list as it is also regulated by the NRC once it has been compounded with its radioactive component Tc-99m Pertechnetate